STERIS plc (Ireland) (STE) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

STERIS plc (Ireland)

NYSE•Healthcare•Medical Devices

$208.04-1.86(-0.01%)After hours

Market Cap

$20.49B

P/E

25.4x

P/S

3.4x

P/B

2.8x

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.

How this company scores

ExcellentMetricSide Score: 80/100

Strongest: Growth (21/25); weakest: Balance Sheet & Red Flags (18/25).

Profitability20/25

Growth21/25

Balance Sheet & Red Flags18/25

Cash & Earnings Quality21/25

Strengths

Strong marginsRising earningsLow leverageCash-backed earnings

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 25.4x5y range 25.4x – 182.8x

Currently below its 18-quarter median.

P/S · 3.4x5y range 3.4x – 5.8x

Currently near its 20-quarter median.

P/B · 2.8x5y range 2.8x – 3.8x

Price & Volume

Market Cap $20.49B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $6.04B
Q. Revenue: $1.49B
TTM EBITDA: $1.88B
TTM Op. Income: $1.14B
Q. Op. Income: $285.80M
TTM Net Income: $805.00M
Q. Net Income: $200.10M
EPS: N/A
Shares Out.: $97.60M

$6.04B in TTM revenue grew 8.4% YoY, reaching $1.49B last quarter. TTM EBITDA of $1.88B and TTM operating income of $1.14B show growth is flowing through to the bottom line. TTM net income of $805.00M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 6 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 45.8%
EBITDA Margin: 27.4%
Op. Margin: 19.1%
Net Margin: 13.4%

Op. margin of 19.1% is up 1.5% YoY — cost efficiency is improving. Net margin at 13.4% and gross margin of 45.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 8% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 25.4x
P/S Ratio: 3.4x
P/B Ratio: 2.8x

At 25.4x P/E, the stock trades within typical market levels. P/S of 3.4x and P/B of 2.8x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $10.74B
Cash: $482.30M
Long-Term Debt: $1.65B
Book Value: $7.21B
D/E Ratio: 0.2
Debt/EBITDA: 4.0

With $10.74B in assets and $1.65B in long-term debt, D/E is 0.2and book value is $7.21B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 7 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $367.10M
TTM Free Cash Flow: $925.60M
FCF Margin: 15.3%
FCF / Net Income: 1.1

TTM FCF of $925.60M on $367.10M in operating cash flow. The FCF / Net Income ratio of 1.1x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 2% — a weakening trend.